• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Increasing potential for in vitro diagnostics in drug development process

Report: Increasing potential for in vitro diagnostics in drug development process

July 30, 2014
CenterWatch Staff

Bionest Partners, a life science industry strategic consulting firm, has found an increased potential for in vitro diagnostics in the drug development process.

Robert J. Easton and Alain J. Gilbert, Bionest co-chairmen, along with Olivier Lesueur, managing partner; Rachel Laing, senior consultant; and Mark Ratner authored the article When Illumina Buys Roche: The Dawning of the Era of Diagnostics Dominance, which details their findings.

According to the article, today’s diagnostics companies are no longer to be viewed as “tools” operations, but rather as having the deep resources and technology platforms to move beyond their former position as an adjunct to the drug development process. They can, in fact, “create and pursue a strategy of information gathering and informatics application to create medical knowledge, enabling them to create medical knowledge, assume risk and manage certain segments of patients.”

According to the article, this evolution from an information specialist to a true development partner is a natural progression for companies within this category and places them in the position to also earn a “higher valuation than less-aggressive players who only supply compartmentalized drug and device solutions.”

“Historically, diagnostics companies have been compartmentalized as commodity enterprises with limited value,” said Gilbert, “and given limited opportunity to play anything other than a subordinate role in developing medicines. These newly-fortified and resource-rich diagnostic companies now are in a position to leverage the data that they generate to create critical medical knowledge that will be of enormous value to their pharmaceutical partners and their patients.”

“The industry already is witnessing the impact and future use of this rich information in therapeutic areas such as oncology where intricate genomic tests often provide physicians with the ability to help classify a patient’s cancer,” said Easton. “The potential for diagnostics to impact the clinical setting already is being achieved, but the economic capability is what will help create a more robust value proposition within the industry.”

The article cites the need for diagnostic companies to move away from their historical position as a utility to a full-fledged development partner with a “broader view of the proteomic and genomic information they are amassing with a panoply of markers—instead of the atomistic one-drug, one-marker mentality that still pervades—they could envision building a better model for drug discovery, eventually adding on other information such as ion measurements and blood glucose, and getting to the point of being able to advise a patient. And it is the ability to perform that advisory function that will add tremendous value above what any single test provides.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing